Non Alcoholic Steatohepatitis Nash Metabolic Contributors And Therapeutic Targets

The cirrhotic liver is significantly more vulnerable to injury. This vulnerability is particularly evident after the advent of portal hypertension. In the normal liver, up to 75 percent can be resected without decompensation. By contrast, in the cirrhotic liver with portal hypertension, liver decompensation can occur even after less than 50 percent of the liver is resected. This book begins with an attempt to provide insights into this unanswered puzzle. The normal liver is soft and elastic. By contrast, the cirrhotic liver is inelastic and rigid. Flow in rigid tubes is governed by the Hagen-Poiseuille law. The law dictates that pressure gradient increases exponentially by the fourth power of the radius of the rigid sinusoid. This makes the cirrhotic liver virtually incapable of accommodating any increase in flow. The increase in pressure gradient is equivalent to the fourth power of the vessel radius. The first chapter explores the major new insight that decompensation in the cirrhotic liver is related to the loss of elasticity and the development of vessel wall rigidity, which thereafter subjects flow in the hepatic sinusoids to the Hagen-Poiseuille law. The rest of the book addresses portal hypertension in its clinical context. It invites the reader to survey multiple avenues associated with portal hypertension, including idiopathic non-cirrhotic portal hypertension, INCPH and non-alcoholic fatty liver disease, NAFLD. It also includes chapters on relationships between portal hypertension, the gastrointestinal system and the renal system. In general, the book provides several new insights into portal hypertension.

Authoritative new text from the experts in GI populationstudies This book covers both key methodological issues and the mostimportant information in the field, disease by disease. It focuseson population-based information and studies looking at principlesand approaches to diagnosis and treatment of diseases. GI Epidemiology brings together world authorities inmultiple disciplines for the very first time, to create one clearand comprehensive source. The bulk of the chapters are divided intotwo parts, covering methodological issues and the epidemiology ofspecific GI diseases. Each chapter begins with a list of keypoints, followed by a review written in a clear and simplestyle. The methodologic chapters cover evidence-based medicine,meta-analysis, systematic reviews, genetic and molecularepidemiology, clinical trials, questionnaire design, and healtheconomics. The disease-specific chapters note the current gaps inknowledge and suggest areas for further study. GI Epidemiology serves as both a useful refresher and areliable reference on the methods and techniques used inepidemiological studies for consultants and researchers ingastroenterology. It is also an invaluable tool for fellows/trainees ingastroenterology, candidates for recertification in the combineddisciplines of gastroenterology, pediatric gastroenterology andcolorectal surgery, and anyone completing MPH training.

This book is a printed edition of the Special Issue "Non-Alcoholic Fatty Liver Disease Research 2016" that was published in IJMS

This book aims to aid the selection of the most appropriate methods for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and related cardiometabolic disorders. Clinical research methods to assess the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycemic clamp technique, have become well-established in proof-of-mechanism studies. However, selection of the most appropriate techniques is by no means straightforward. Moreover, the application of such methods must conform to the regulatory requirements for new drugs. This book discusses the need for new pharmacotherapies for diabetes, obesity and NAFLD and the molecular targets of drugs currently in development. Emerging technologies including functional imaging, circulating biomarkers and omics are considered together with practical and ethical issues pertaining to early phase clinical trials in subjects with cardiometabolic disorders. Translational Research Methods in Diabetes, Obesity, and Non-Alcoholic Fatty Liver Disease is of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.